Boehringer Ingelheim and DCRI expand collaboration to create largest patient registry for IPF
Boehringer Ingelheim Pharmaceuticals, Inc. and the DCRI announced today the expansion of the Idiopathic Pulmonary Fibrosis – PROspective Outcomes (IPF-PRO) Registry, a patient registry developed to uncover insights into IPF, a rare and serious lung disease. The expansion will increase the study enrollment from 300 patients at 18 study sites to 1,500 patients at approximately 45 sites, creating the largest registry of newly diagnosed IPF patients.
New NIH-funded center to study inefficiencies in clinical trials
The center will be a key component of the Trial Innovation Network, which is the newest part of the Clinical and Translational Science Award Program.
DIA 2016: DCRI researchers discuss how ADAPTABLE could change clinical trials
The DCRI’s Adrian Hernandez, MD, MHS, and Lesley Curtis, PhD, examined the challenges and opportunities of running one of the largest pragmatic clinical trials.